MONTREAL, Nov. 17, 2016 -- Ropack Pharma Solutions announces it will launch an international serialization hub as a practical solution for pharmaceutical organizations and contract packaging partners that are not serialization-ready by the Drug Supply Chain Security Act (DSCSA) mandated deadline.
Through the serialization hub, packaged pharmaceutical products are sent by an organization’s in-house packaging team or contract partners to Ropack’s Montreal facility. There the packaged products are serialized as required – to the product, the carton or the palette. The serialized product is then shipped, as directed, to a distribution network in the U.S. or Canada, a warehouse for aggregation with other orders or to international destinations which have already adopted serialization.
“Our serialization hub is an efficient alternative,” notes Paul Dupont, Ropack’s VP of Marketing and Business Development. “Becoming serialization-ready is a complex, time-consuming and expensive undertaking which is not practical for every company.” Dupont points out that his company’s serialization hub reduces an organization’s capital expenditures, need for increased personnel and the multifaceted coordination serialization requires.
“A significant benefit is that pharma companies can continue to use their trusted contract packagers – or in-house team – then outsource the serialization component to Ropack.”
According to Dupont, an added benefit is that international shipping from Canada is significantly easier than from the U.S.
Ropack Pharma Solutions (RPS) brings solid oral dosage packaging solutions to leading pharmaceutical and natural health organizations: bottle, flip-top vial, blister (cold formed and thermoformed), stick-packs, sachets, strip-packs. RPS's International Serialization Hub will provide a practical solution for organizations not serialization-ready by November 2017. Headquartered in Montreal, RPS offers the highest level of quality along with gold-standard technology and a responsive, cross-trained staff. Since 1976.
Contact: Paul Dupont, VP Marketing and Business Development Ropack, Inc. [email protected] 513.846.0921


TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering
Apple Turns 50: From Garage Startup to AI Crossroads
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal
Britain Courts Anthropic Amid US Defense Department Dispute
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 



